High dose intravenous immunoglobulin therapy: Dermatologic applications;Einsatz hochdosierter intravenöser immunglobuline in der Dermatologie

JDDG - Journal of the German Society of Dermatology

Volumn 1, Issue 3, 2003, Pages 183-190

  Enk, Alexander ^a   Hertl, Michael ^b   Messer, Gerald ^b   Meurer, Michael ^b   Rentz, Ellen ^b   Zillikens, Detlef ^b  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^b NONE

Author keywords

Clinical application; Immunoglobulins; Standards

Indexed keywords

DERMATOLOGICAL AGENT; IMMUNOGLOBULIN;

CLINICAL PRACTICE; DERMATOMYOSITIS; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG INDICATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENCY; DRUG QUALITY; DRUG SPECIFICITY; DRUG SYNTHESIS; EPIDERMOLYSIS BULLOSA; HEALTH CARE COST; HUMAN; IMMUNOGLOBULIN A DEFICIENCY; IMMUNOTHERAPY; PEMPHIGUS VULGARIS; PRACTICE GUIDELINE; PYODERMA GANGRENOSUM; REVIEW; SKIN DISEASE; STANDARD; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; TOXIC EPIDERMAL NECROLYSIS; VASCULITIS;

DERMATOLOGY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; GERMANY; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; INJECTIONS, INTRAVENOUS; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES; SKIN DISEASES;

EID: 0038560970     PISSN: 16100379     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1610-0387.2003.02028.x     Document Type: Review

References (36)

1. Basta M. Modulation of complement-mediated immune damage by intravenous immune globulin. Clin Exp Immunol 1996; 104: 21-25.
2. Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune disease with normal polyspecific immunoglobulin G (intravenous immunoglobulin). In: Schoenfeld V: The Decade of Autoimmunity. Elsevier Sci BV, 1999: 409-419.
3. Sewell WAC, North ME, Cumbronero R, Farrant J. In vivo modulation of cytokine synthesis by intravenous immunglobulin. Clin Exp Immunol 1999; 92: 34-48.
4. Europäische Pharmakopoeia. Immunoglobulin humanum normale ad usum intravenosum. Pharm Europa 1993; 5: 365-374.
5. Wolf HM, Eibl MM. Immunomodulatory effect of immunoglobulins. Clin Exp Rheumatol 1996; 14: 17-25.
6. Hammarström L, Gandulf A, Immarstrom V, Janson A, Lindberg K, Smith CI. Systemic and topical immunoglobulin treatment in immunocompromized patients. Immunol Rev 1994; 139: 43-70.
7. Lacroix-Desmazes S. Immunoglobulins and the regulation of autoimmunity through the immune network. Clin Exp Rheumatol 1996; 14: 9-15.
8. Viard I, Wehrli P, Bullani R, Schneider P, Holler N, Salomon D, Hunziker T, Saurat JH, Tschopp J, French LE. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 1998; 282: 490-492.
9. EMEA Committee for Proprietary Medicinal Products. Note for Guidance on virus validation studies: the design, contribution and interpretation of studies validating the inactivation and removal of viruses. CPMP/BWP/268/95, 1996.
10. EMEA Committee for Proprietary Medicinal Products. Note for Guidance on the clinical investigation of human normal immunoglobulin for intravenous administration (IVIg). CPMP/BWPG/388/95 rev 1, 2000.
11. EMEA Committee for Proprietary Medicinal Products. Note for Guidance on plasma-derived medicinal products. CPMP/BWP/269/95 rev 3, 2001.
12. Jainta S, Schmidt E, Bröcker EB, Zillikens D. Diagnostik und Therapie bullöser Autoimmunerkrankungen der Haut. Dtsch Ärztebl 2001; 20: 1320-1325.
13. Engineer L, Bhol K, Ahmed AR. Analysis of current data on the use of intravenous immunoglobulins in management of pemphigus vulgaris. J Am Acad Dermatol 2000; 43: 1049-1057.
14. Jolles S. A review of high-dose intravenous immunoglobulin in the treatment of the autoimmune blistering disorders. Clin Exp Dermatol 2001; 26: 127-131.
15. Wever S, Zillikens D, Bröcker EB. Successful treatment of refractory mucosal lesions of pemphigus vulgaris using intravenous gammaglobulin as adjuvant therapy. Br J Dermatol 1996; 135: 862-863.
16. Admed AR, Colon JE. Comparsion between intravenous immunoglobulin and conventional immunosuppressive therapy regimes in patients with severe oral Pemphigoid. Arch Dermatol 2001; 137: 1181-1189.
17. Rutter A, Luger TA. High-dose intravenous immunoglobulins: an approach to treat severe immunemediated and autoimmune diseases of the skin. J Am Acad Dermatol 2001; 44: 1010-1024.
18. Enk AH, Knop J. Adjuvante Therapie von Pemphigus vulgaris und Pemphigus foliaceus mit intraven̈sen Immunglobulinen. Hautarzt 1998; 49: 774-776.
19. Messer G, Sizmann N, Feucht H, Meurer M. High-dose intravenous immunoglobulins for immediate control of pemphigus vulgaris. Br J Dermatol 1995; 133: 1014-1015.
20. Volc-Platzer B. Immunoglobulin treatment in dermatology. Hautarzt 2001; 52: 264-277.
21. Dalakas MC. Controlled studies with high-dose intravenous immunoglobulin in the treatment of dermatomyositis, inclusion body myositis, and polymyositis. Neurology 1998; 51: 37-45.
22. Cherin P, Herson S, Wechsler B, Piette JC, Bletry O, Coutellier A, Ziza JM. Efficacy of intravenous gammaglobulin therapy in chronic refractory polymyositis and dermatomyositis: an open study with 20 adult patients. Am J Med 1991; 91: 162-168.
23. Mastaglia FL, Phillips BA, Zilko PJ. Immunoglobulin therapy in inflammatory myopathies J Neurol Neurosurg Psychiatry 1998; 65: 107-110.
24. Göttfried I, Seeber A, Anegg B, Rieger A, Stingl G, Volc-Platzer B. High dose intravenous immunoglobulin (IVIG) in dermatomyositis; clinical responses and effect on sIL2R levels. Eur J Dermatol 2000; 10: 29-35.
25. Sansome A, Dubowitz V. Intravenous immunoglobulins in juvenile dermatomyositis - four year review of nine cases. Arch Dis Child 1995; 72: 25-28.
26. Rostoker G, Desvaux-Belghiti D, Pilatte Y, Petit-Phar M, Philippon C, Deforges L, Terzidis H, Intrator L, Andre C, Adnot S. High-dose immunoglobulin therapy for severe IgA nephropathy and Henoch-Schonlein purpura. Ann Intern Med 1994; 120: 476-484.
27. Jayne DR, Chapel H, Adu D, Misbah S, O'Donoghue D, Scott D, Lockwood CM. IVIG in vasculitis. QJM 2000; 93: 433-439.
28. Phan TG, Wong RCW, Crotty K, Adelstein S. Toxic epidermal necrolysis in acquired immunodeficiency syndrome treated with intravenous gammaglobulin. Austr J Dermatol 1999; 40: 153-157.
29. Francioni C, Galeazzi M, Fioravanti A, Gelli R, Megale F, Marcolongo R. Long term i. v. Ig treatment in systemic lupus erythematosus. Clin Exp Rheumatol 1994; 12: 163-168.
30. Schroeder JO, Zeuner RA, Euler HH, Löffler H. High dose intravenous immunoglobulins in systemic lupus erythematosus: clinical and serological results of a pilot study. J Rheumatol 1996; 23: 71-75.
31. Boletis JN, Ioannidis JPA, Boki KA, Moutsopoulos HM. Intravenous immunoglobulin compared with cyclophosphamide for proliferative lupus nephritis. Lancet 1999; 354: 569-570.
32. Gelfand EW, Landwehr LP, Esterl B, Mazer B. Intravenous immune globulin: an alternative therapy in steroid-dependent allergic diseases. Clin Exp Immunol 1996; 104: 61-66.
33. Dirschka T, Karstner A, Behrens U, Altmeyer P. Successful treatment of pyoderma gangrenosum with intravenous human immunoglobulin. J Am Acad Dermatol 1998; 39: 789-790.
34. Meier F, Sönnichsen K, Schaumburg-Lever G, Dopfer R, Rassner G. Epidermolysis bullosa acquisita: efficacy of high-dose intravenous immunoglobulins. J Am Acad Dermatol 1993; 29: 334-337.
35. Mohr C, Sunderkötter C, Hildebrand A, Bie K, Rütter A, Luger TA, Kolde G. Successful treatment of epidermolyis bullosa acquisita using intravenous immunoglobulins. Br J Dermatol 1995; 132: 824-826.
36. Kroiss MM. High-dose intravenous immune globulin is also effective in linear IgA disease. Br J Dermatol 2000; 142: 582.